Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/14/2008

BOULDER, Colo. and MONTREAL, Feb. 14 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of acute myelogenous leukemia (AML) in the United States. Criteria for designation require that the product be intended for treatment of a condition affecting fewer than 200,000 people in the United States, and the application must include a rationale for the use of the drug in the rare disease or condition.

Orphan Drug Designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition. These incentives include, tax credits, research and development grant funding, and reduced filing fees at the time of application for marketing approval. Once approved, the product may qualify for seven years of marketing exclusivity in the United States.

About MGCD0103

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in one Phase I combination clinical trial with Taxotere(R) for solid tumors, two Phase I/II combination trials with Vidaza(R) for hematological malignancies and with Gemzar(R) for pancreatic cancer, and five Phase II clinical trials in hematological malignancies.

MGCD0103 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and has been designated an Orphan Medicinal Product by the EMEA for the treatment of Hodgkin lymphoma and acute myelogenous leukemia.

About Acute Myelogenous Leukemia (AML)

Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow that
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
8. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
9. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
10. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
11. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... MOUNTAIN VIEW, Calif. , May 21, 2013 /PRNewswire/ ... Brazil , Russia , ... (BRIC) are realizing there are no shortcuts.  This ... especially in the United States.  Companies must change the ... establishing value, customizing to local needs, and building regional ...
(Date:5/21/2013)... -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: ... cell based therapies for various personal applications, announced that ... CEO, will be presenting at the Marcum MicroCap Conference.   ... Thursday, May 30, 2013 at the Grand Hyatt Hotel, ... City.  Mr. Weinreb,s presentation will take place at 2:30 ...
(Date:5/21/2013)... 21, 2013  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization ... acute and breakthrough pain, today announced top-line ... 3 study of its investigational sublingual Sufentanil ... the primary efficacy endpoint was achieved.  The ...
Breaking Medicine Technology:Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... Pharmaceutical and healthcare market research company ... report, " Consumer Online Health Video : ... consumer demand for online health video and the impact ... health video has increased significantly among U.S. consumers online ...
... U.S. hospitals today reported significant progress in the fight ... and presented by clinicians from St. Joseph,s Mercy Hospital ... and the VA Medical Center in Seattle showed that ... some 62,500 hospital patients nationwide. (Logo: ...
Cached Medicine Technology:New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format 2Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 2Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 3Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 4
(Date:5/21/2013)... Mass. (PRWEB) May 21, 2013 Dimensional ... today announced that Western Maryland Health System, ... be using The Diver Solution™ (Diver) to help it ... is the first customer to purchase Diver through Dimensional ... , Like most hospitals, Western Maryland has massive ...
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Tools4ever, ... solutions, has made its Self Service Reset Password Management ... SSRPM, employees can now use the service on mobile ... that end users can easily reset their Windows passwords ... set of questions correctly, the user may then reset ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... physical activity appears to be an independent predictor ... pulmonary disease (COPD) will end up being hospitalized, ... in Connecticut. The study also corroborates an earlier ... an increased incidence of hospitalizations among patients with ... be presented at the ATS 2013 International Conference. ...
(Date:5/21/2013)... 2013 Barbara Michels, author of “ ... over 50 years of experience in the world of ... both her mom and dad to Alzheimer’s disease ... volunteer with the New Mexico Chapter of the Alzheimer’s ... and insight into the many challenges caregivers experience. Through ...
Breaking Medicine News(10 mins):Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Exercise levels may predict hospitalizations in COPD population 2Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 2Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 3Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 4
... Accelerated growth of tumors seen in mouse study , , ... in the inorganic phosphates found in many natural and ... rats, South Korean researchers report. , "Our study suggests ... for lung cancer treatment as well as prevention," Myung-Haing ...
... among those whose families don,t accept them , , MONDAY, ... families rejected them when they were younger are more ... use and suicide attempts, new research suggests. , The ... a child,s sexuality directly causes problems later in life. ...
... high-fat diet can not only lead to overweight because ... balance of circadian rhythms everyone,s 24-hour biological clock, ... The biological clock regulates the expression and/or activity of ... the clock can lead to such phenomena as hormone ...
... Second Harvest Heartland, the,Upper Midwest,s largest hunger relief ... General Mills and NBC,s "The Biggest Loser.",Through the ... dieters,in Minnesota and western Wisconsin pledge to lose ... cents to Second Harvest Heartland -- enough to ...
... bean plant Ricinus communis is considered one of the ... tissue damage and inflammation and can result in death. ... of castor beans whereby the toxin is released after ... severe gastrointestinal damage with symptoms and death due to ...
... for the relief of fever, headaches, and other minor ... are well documented and acetaminophen is accepted to be ... of short-term, especially high-dose NSAID and acetaminophen use have ... be published on November 21 , 2008 in the ...
Cached Medicine News:Health News:Food Phosphates Might Spur Lung Cancer 2Health News:Food Phosphates Might Spur Lung Cancer 3Health News:Rejection of Gay Teens Linked to Later Troubles 2Health News:Rejection of Gay Teens Linked to Later Troubles 3Health News:Another reason to avoid high-fat diet -- it can disrupt our biological clock 2Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 2Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 3Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 4Health News:Acute gastric injury due to high-dose analgesics? 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... reduces joint instability without disturbing hand ... comfortable and easy for users to ... and Robert V. Sypher Jr., MD, ... response to patients' complaints of discomfort ...
... The ThumSaver MP stabilizes the MP joint and the ... to reduce subluxation of both of the thumb joints. ... to eliminate pain, but who need maximum mobility for ... base of the thumb and for those with pain ...
... thumb splint is molded from rigid plastic in ... application and wearing comfort. The uniquely sculpted ... fingers and preserves maximum function of the hand. ... DeQuervain's Tendonitis, strains and sprains of the MCP ...
Medicine Products: